Determination of azapropazone in its pharmaceutical form by HPLC and flow injection analysis

Abstract

Azapropazone is an analgesic and anti-inflammatory agent that is used in the treatment of musculoskeletal and joint disorders, as well as in acute gout, because of its uricosuric properties. A simple and sensitive high performance liquid chromatographic method (HPLC), for the determination of azapropazone in its pharmaceutical form has been developed and validated. Azapropazone and indapamide (internal standard) were separated by a reversed phase column (Supelco Hypersil 5 mu m, 150 x 4.6 mm ID, C-18) with a mobile phase consisting of K2HPO4 (0.1 M) and methanol (55: 45, v/v) (at pH 7.0). The mobile phase was pumped at 1.2 mL min(-1) flow rate then azapropazone was determined by ultraviolet detection at 251 nm. The method has an average analysis time of 5.81 min. for azapropazone. The flow injection analysis (FIA) was performed by using a carrier stream of ethanol: water (10:90, v/v) with a flow rate of 1.2mL min(-1). The LOD and LOQ concentrations of azapropazone for the two methods were 2.77 x 10(-8) M and 8.41 x 10(-8) M for HPLC, 3.65 x 10(-7) M and 1.10 x 10(-6) M for FIA, respectively. The results obtained from the analysis of capsule samples using both methods were compared by common statistical tests. There was no significant difference observed between the methods.